The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease

被引:0
|
作者
Lee, Ju Kwang [1 ]
Kim, Seonok [2 ]
Chong, Yong Pil [3 ]
Lee, Hyun Joo [4 ]
Shim, Tae Sun [5 ]
Jo, Kyung-Wook [5 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea
[5] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
all-cause mortality; cavitary type; Mycobacterium avium complex; treatment outcome; TREATMENT OUTCOMES; LUNG-DISEASE; TUBERCULOSIS;
D O I
10.1016/j.chest.2024.03.027
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: The association between treatment outcome and the mortality of patients with Mycobacterium avium complex pulmonary disease (MAC-PD) with cavitary lesions is unclear. This article assessed the impact of culture conversion on mortality in patients with cavitary RESEARCH QUESTION: Is the achievement of sputum culture conversion in patients with MAC-PD with cavitary lesions associated with the prognosis? STUDY DESIGN AND METHODS: From 2002 to 2020, a total of 351 patients with cavitary MAC-PD (105 with the fibrocavitary type and 246 with the cavitary nodular bronchiectatic type), who had been treated with a >= 6-month macrolide-containing regimen at a tertiary referral center in South Korea, were retrospectively enrolled in this study. All-cause mortality during the follow-up period was analyzed based on culture conversion at the time of treatment completion. RESULTS: The cohort had a median treatment duration of 14.7 months (interquartile range [IQR], 13.4-16.8 months). Of the 351 patients, 69.8% (245 of 351) achieved culture conversion, and 30.2% (106 of 351) did not. The median follow-up was 4.4 years (IQR, 2.3-8.3 years) in patients with culture conversion and 3.1 years (IQR, 2.1-4.8 years) in those without. For the patients with and without culture conversion, all-cause mortality was 5.3% vs 35.8% (P < .001), and the 5-year cumulative mortality was 20.0% vs 38.4%, respectively. Cox analysis found that a lack of culture conversion was significantly associated with higher mortality (adjusted hazard ratio, 5.73; 95% CI, 2.86-11.50). Moreover, the 2-year landmark analysis revealed a distinct impact of treatment outcome on mortality. INTERPRETATION: The mortality rate of patients with cavitary MAC-PD who did not achieve culture conversion was significantly higher than that of those with culture conversion.
引用
收藏
页码:442 / 451
页数:10
相关论文
共 50 条
  • [31] Cavitary Pulmonary Infection With Mycobacterium avium Observed by Bronchoscopy
    Uruga, Hironori
    Suzuki, Aika
    Hanada, Shigeo
    Takaya, Hisashi
    Miyamoto, Atsushi
    Morokawa, Nasa
    Fujii, Takeshi
    Kurosaki, Atsuko
    Kishi, Kazuma
    JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY, 2012, 19 (04) : 332 - 335
  • [32] Post-treatment Radiographic Severity and Mortality in Mycobacterium avium Complex Pulmonary Disease
    Kim, Joong-Yub
    Lee, Seowoo
    Park, Hyungin
    Kim, Hyung-Jun
    Lee, Hyun Woo
    Lee, Jae Ho
    Yim, Jae-Joon
    Kwak, Nakwon
    Yoon, Soon Ho
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (02) : 235 - 242
  • [33] Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection
    Kikuchi, T.
    Watanabe, A.
    Gomi, K.
    Sakakibara, T.
    Nishimori, K.
    Daito, H.
    Fujimura, S.
    Tazawa, R.
    Inoue, A.
    Ebina, M.
    Tokue, Y.
    Kaku, M.
    Nukiwa, T.
    THORAX, 2009, 64 (10) : 901 - 907
  • [34] Serodiagnosis of Pulmonary Disease Due to Mycobacterium avium Complex Proven by Bronchial Wash Culture
    Kitada, Seigo
    Kobayashi, Kazuo
    Nishiuchi, Yukiko
    Fushitani, Kenji
    Yoshimura, Kenji
    Tateishi, Yoshitaka
    Miki, Keisuke
    Miki, Mari
    Hashimoto, Hisako
    Motone, Masaharu
    Fujikawa, Takeya
    Hiraga, Tarn
    Maekura, Ryoji
    CHEST, 2010, 138 (01) : 236 - 237
  • [35] A marmoset model for Mycobacterium avium complex pulmonary disease
    Peters, Jay
    Maselli, Diego Jose
    Mangat, Mandeep
    Coalson, Jacqueline J.
    Hinojosa, Cecilia
    Giavedoni, Luis
    Brown-Elliott, Barbara A.
    Chan, Edward
    Griffith, David
    Subbian, Selvakumar
    Subbian, Selvakumar
    Subbian, Selvakumar
    Subbian, Selvakumar
    Subbian, Selvakumar
    PLOS BIOLOGY, 2023, 21 (03)
  • [36] Treatment of pulmonary disease caused by Mycobacterium avium complex
    Shimokata, K
    INTERNAL MEDICINE, 2003, 42 (08) : 627 - 628
  • [37] A Case of Familial Pulmonary Mycobacterium avium Complex Disease
    Matsuyama, Masashi
    Miura, Yukiko
    Kiwamoto, Takumi
    Moriya, Ataru
    Kokuho, Nariaki
    Shimizu, Kei
    Otsuka, Shigeo
    Hijikata, Minako
    Keicho, Naoto
    Hayashihara, Kenji
    Saito, Takefumi
    INTERNAL MEDICINE, 2010, 49 (10) : 949 - 953
  • [38] Monotherapy With Erythromycin for Mycobacterium avium Complex Pulmonary Disease
    Yano, Yukihiro
    Kitada, Seigo
    Mori, Masahide
    Yokota, Soichiro
    Maekura, Ryoji
    CHEST, 2014, 145 (03)
  • [39] Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA
    Kitada, Seigo
    Levin, Adrah
    Hiserote, Melissa
    Harbeck, Ron J.
    Czaja, Chris A.
    Huitt, Gwen
    Kasperbauer, Shannon H.
    Daley, Charles L.
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (02) : 454 - 460
  • [40] A marmoset model for Mycobacterium avium complex pulmonary disease
    Peters, Jay
    Maselli, Diego Jose
    Mangat, Mandeep A.
    Coalson, Jacqueline. J.
    Hinojosa, Cecilia
    Giavedoni, Luis
    Brown-Elliott, Barbara. A.
    Chan, Edward
    Griffith, David
    PLOS ONE, 2023, 18 (03):